ESC CONGRESS 2018 – SATELLITE SYMPOSIUM

Cardiovascular Risk Reduction and the Role of Lipoprotein(a): Present and Future Therapeutic Options

COMPLIMENTARY LUNCH SATELLITE SYMPOSIUM

Sunday August 26, 2018
13:00-14:00
Damascus-Spotlight Village
Munich, Germany
www.cccfme.org/CVRisk2018
PROGRAM OVERVIEW
The robust and specific association between elevated Lp(a) levels and increased cardiovascular disease risk, together with recent genetic findings, indicates that elevated Lp(a), like elevated LDL cholesterol, is causally related to premature CVD, yet there remains significant knowledge gaps in fully understanding the role of Lp(a) in CVD and inadequate understanding of the mechanisms underlying current drug therapies on Lp(a) levels.

This program will review the current understanding of the structure, genetics, and function of Lp(a) as well as indications for screening and current and future treatment strategies.

LEARNING OBJECTIVES
1) Critically evaluate Lp(a) as a cardiovascular risk factor for premature CVD
2) Have greater competence in recognizing populations who may benefit from screening and Lp(a) -lowering therapies
3) Recognize the potential role of emerging pharmacologic therapies to reduce Lp(a) in those at high risk for cardiovascular disease

COURSE DIRECTORS
Leslie Cho, MD
Cleveland Clinic
Cleveland, OH
Katherine Hoercher, RN
Cleveland Clinic
Cleveland, OH

FACULTY
Leslie Cho, MD
Cleveland Clinic
Cleveland, Ohio
Sotirios Tsimikas, MD
University of California San Diego La Jolla, California
Steven Nissen, MD
Cleveland Clinic
Cleveland, Ohio

AGENDA  SUNDAY AUGUST 26, 2018  |  13:00-14:00
CHAIR: Leslie Cho, MD

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:00 - 13:17</td>
<td>Basic Science and Mechanism of Action of Lp(a)</td>
<td>Sotirios Tsimikas, MD</td>
</tr>
<tr>
<td>13:17 - 13:34</td>
<td>Epidemiology and Clinical trial Data of Lp(a)</td>
<td>Leslie Cho, MD</td>
</tr>
<tr>
<td>13:34 - 13:51</td>
<td>Current and Future Treatment Strategies to Lower Lp(a)</td>
<td>Steven Nissen, MD</td>
</tr>
<tr>
<td>13:51 - 14:00</td>
<td>Panel Discussion and Q &amp;A</td>
<td></td>
</tr>
</tbody>
</table>
Cleveland Clinic’s Sydell and Arnold Miller Family Heart & Vascular Institute is one of the largest cardiovascular and thoracic specialty groups in the world. Experts provide the latest in medical and surgical care, all enhanced by advanced technology, research and education. It has been ranked No. 1 in America for heart care for 23 years in a row. The Miller Family Heart & Vascular Institute is one of 27 institutes at Cleveland Clinic, a nonprofit, academic medical center ranked among the nation's top hospitals (U.S. News & World Report), where more than 3,200 staff physicians and researchers in 120 specialties collaborate to give every patient the best outcome and experience.

To learn more about Cleveland Clinic’s Miller Family Heart & Vascular Institute, visit clevelandclinic.org/heart.